Base de dados : MEDLINE
Pesquisa : A01.923.176 [Categoria DeCS]
Referências encontradas : 4009 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 401 ir para página                         

  1 / 4009 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29480829
[Au] Autor:Linhas R; Tente D; China N; Conde S; Barroso A
[Ad] Endereço:Department of Pulmonology.
[Ti] Título:Subcutaneous metastasis of a pulmonary carcinoid tumor: A case report.
[So] Source:Medicine (Baltimore);97(2):e9415, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Carcinoid tumors are derived from neuroendocrine cells and are most frequently found in the gastrointestinal tract and bronchopulmonary system. They are generally characterized by an indolent clinical course but may in some instances spread to regional lymph nodes or to distant sites. Subcutaneous metastases of carcinoid tumors are extremely rare; there are only few cases reported in the literature and the site of the primary tumor was mainly the gastrointestinal tract. Also, the diagnosis of this type of lesions many years after the surgical resection of the pulmonary carcinoid (PC) could be a challenge for clinicians. PATIENT CONCERNS: A nonsmoker woman diagnosed with a atypical carcinoid stage IA2 maintained follow-up at our institution. Seven years later she incidentally detected a subcutaneous nodular lesion in the lumbar region. DIAGNOSES: A positron emission tomography-computed tomography (PET/CT) was performed and showed pathological uptake of the refered lesion. An excisional biopsy was performed and with the support of immunohistochemistry the diagnosis of a subcutaneous metastasis from a pulmonary atypical carcinoid was made. INTERVENTIONS: The patient initiated chemotherapy with carboplatin plus etoposide and complied 4 cycles of treatment. OUTCOMES: She maintained tight follow-up at our center and for 12 months there were no signs of relapse. LESSONS: This extremely rare case highlights the difficulties in the differential diagnosis and the importance of diagnostic tests as PET/CT and immunohistochemistry in the establishment of a diagnosis. Physicians should be aware of signs of skin metastasis from lung malignancies even if the prognosis is good or many years have passed since the surgical resection.
[Mh] Termos MeSH primário: Tumor Carcinoide/patologia
Neoplasias Pulmonares/patologia
Neoplasias Cutâneas/secundário
[Mh] Termos MeSH secundário: Adulto
Dorso
Tumor Carcinoide/diagnóstico por imagem
Tumor Carcinoide/tratamento farmacológico
Feminino
Seres Humanos
Neoplasias Pulmonares/diagnóstico por imagem
Neoplasias Pulmonares/tratamento farmacológico
Neoplasias Cutâneas/diagnóstico por imagem
Neoplasias Cutâneas/tratamento farmacológico
Neoplasias Cutâneas/patologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180227
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009415


  2 / 4009 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29182000
[Au] Autor:Beattie G; Tai C; Pinar Karakas S; Cham E; Idowu O; Kim S
[Ad] Endereço:Department of Surgery, University of California San Francisco-East Bay Oakland, CA United States.
[Ti] Título:Colossal pilomatrixoma.
[So] Source:Ann R Coll Surg Engl;100(2):e38-e40, 2018 Feb.
[Is] ISSN:1478-7083
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:We describe the largest reported case of pilomatrixoma in the literature. While pilomatrixomas typically present as small soft-tissue nodules of the head, neck and upper extremities, they can also present as much larger masses in atypical locations. When they present in their usual size, pilomatrixomas have typical imaging features and can be correctly diagnosed with imaging studies before histological confirmation. Their clinical and imaging diagnosis become challenging when they are very large, as in our case. A giant pilomatrixoma should also be considered for paediatric patients presenting with a large subcutaneous soft-tissue mass.
[Mh] Termos MeSH primário: Dorso
Doenças do Cabelo
Pilomatrixoma
Neoplasias Cutâneas
[Mh] Termos MeSH secundário: Adolescente
Dorso/patologia
Dorso/cirurgia
Doenças do Cabelo/diagnóstico
Doenças do Cabelo/patologia
Doenças do Cabelo/cirurgia
Seres Humanos
Masculino
Pilomatrixoma/diagnóstico
Pilomatrixoma/patologia
Pilomatrixoma/cirurgia
Pele/patologia
Neoplasias Cutâneas/diagnóstico
Neoplasias Cutâneas/patologia
Neoplasias Cutâneas/cirurgia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180209
[Lr] Data última revisão:
180209
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171129
[St] Status:MEDLINE
[do] DOI:10.1308/rcsann.2017.0196


  3 / 4009 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28723766
[Au] Autor:Maharjan S; Li X; Cui J; Liu Y; Lu L
[Ad] Endereço:Department of Hand and Foot Surgery, The First Hospital of Jilin University, Changchun, Jilin Province, P.R. China.
[Ti] Título:Lady with wings: a case report of giant neurofibromatosis type I.
[So] Source:Medicine (Baltimore);96(29):e7523, 2017 Jul.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Neurofibromatosis type I (NF-I) accounts for approximately 90% of neurofibromatosis. NF-I is an autosomal dominant genetic disease which results from the gene mutation of NF-I situated in chromosome 17q11.2. PATIENT CONCERNS: A 32-year-old lady presented with a giant wing like structure on her back which started growing from her childhood. DIAGNOSIS: A diagnosis of NF-I was confirmed as she presented with multiple cutaneous nodules, multiple café-au-lait macules of different sizes, scoliosis deformity, and positive family history of neurofibroma. INTERVENTIONS: Surgical excision of tumor and multiple Z plasty reconstruction of the back was carried out. OUTCOMES: The excised neurofibroma weighed 6.7 kg containing thickened nerves, nerve roots, and circuitous vessels. The histopathological report confirmed plexiform and diffuse type cutaneous neurofibroma without any malignant transformation. Surgical excision and reconstruction with regular follow-up is an excellent choice of treatment for such a giant neurofibroma as in this case. LESSONS: NF-I is a genetic disease which could present as a giant cutaneous neurofibroma. One of the treatment options for giant neurofibromas causing deformity and physical disability is by surgical excision and histopathological examination with regular follow-up for NF-I recurrence.
[Mh] Termos MeSH primário: Neurofibromatose 1/diagnóstico
Neurofibromatose 1/cirurgia
Neoplasias Cutâneas/diagnóstico
Neoplasias Cutâneas/cirurgia
[Mh] Termos MeSH secundário: Adulto
Dorso/diagnóstico por imagem
Dorso/patologia
Dorso/cirurgia
Diagnóstico Diferencial
Feminino
Seres Humanos
Neurofibromatose 1/patologia
Procedimentos Cirúrgicos Reconstrutivos
Neoplasias Cutâneas/patologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170801
[Lr] Data última revisão:
170801
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170721
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000007523


  4 / 4009 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28677485
[Au] Autor:Greis C; Lautenschlager S
[Ad] Endereço:1 Dermatologisches Ambulatorium, Stadtspital Triemli, Zürich.
[Ti] Título:CME-Dermatologie 13/Auflösung: Peitschenhiebartige Läsionen..
[So] Source:Praxis (Bern 1994);106(14):795-796, 2017 Jul.
[Is] ISSN:1661-8157
[Cp] País de publicação:Switzerland
[La] Idioma:ger
[Mh] Termos MeSH primário: Hipersensibilidade Alimentar/diagnóstico
Cogumelos Shiitake
[Mh] Termos MeSH secundário: Adulto
Dorso
Diagnóstico Diferencial
Seres Humanos
Masculino
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170828
[Lr] Data última revisão:
170828
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170706
[St] Status:MEDLINE
[do] DOI:10.1024/1661-8157/a002712


  5 / 4009 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28595242
[Au] Autor:Choi SY; Choi EJ; Suh JH; Kim BJ
[Ad] Endereço:Department of Dermatology, Seoul Paik Hospital, Inje University College of Medicine, Seoul, South Korea, Department of Dermatology, Chung-Ang University College of Medicine, Seoul, South Korea Department of Dermatology, Chung-Ang University College of Medicine, Seoul, South Korea.
[Ti] Título:Three-Dimensional Imaging as a Novel Method of Evaluating the Longevity of Hyaluronic Acid Fillers in a Mouse Model.
[So] Source:Dermatol Surg;43(8):1108-1112, 2017 08.
[Is] ISSN:1524-4725
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Técnicas Cosméticas
Preenchedores Dérmicos/farmacologia
Ácido Hialurônico/farmacologia
[Mh] Termos MeSH secundário: Animais
Dorso/diagnóstico por imagem
Preenchedores Dérmicos/administração & dosagem
Ácido Hialurônico/administração & dosagem
Imagem Tridimensional
Injeções
Imagem por Ressonância Magnética
Camundongos
Modelos Animais
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dermal Fillers); 9004-61-9 (Hyaluronic Acid)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171012
[Lr] Data última revisão:
171012
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170609
[St] Status:MEDLINE
[do] DOI:10.1097/DSS.0000000000001156


  6 / 4009 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28538321
[Au] Autor:da Silva JJ; Schoenfeld BJ; Marchetti PN; Pecoraro SL; Greve JMD; Marchetti PH
[Ad] Endereço:1Department of Human Movement Sciences, Graduate Program in Science of Human Movement, College of Health Science (FACIS), Methodist University of Piracicaba, Piracicaba, São Paulo, Brazil; 2Department of Health Sciences, Program of Exercise Science, CUNY Lehman College, Bronx, New York; and 3Laboratory of Kinesiology, Institute of Orthopedics and Traumatology, School of Medicine, University of São Paulo, São Paulo, Brazil.
[Ti] Título:Muscle Activation Differs Between Partial and Full Back Squat Exercise With External Load Equated.
[So] Source:J Strength Cond Res;31(6):1688-1693, 2017 06.
[Is] ISSN:1533-4287
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Changes in range of motion affect the magnitude of the load during the squat exercise and, consequently, may influence muscle activation. The purpose of this study was to evaluate muscle activation between the partial and full back squat exercise with external load equated on a relative basis between conditions. Fifteen young, healthy, resistance-trained men (age: 26 ± 5 years, height: 173 ± 6 cm) performed a back squat at their 10 repetition maximum (10RM) using 2 different ranges of motion (partial and full) in a randomized, counterbalanced fashion. Surface electromyography was used to measure muscle activation of the vastus lateralis, vastus medialis, rectus femoris, biceps femoris (BF), semitendinosus, erector spinae, soleus (SL), and gluteus maximus (GM). In general, muscle activity was highest during the partial back squat for GM (p = 0.004), BF (p = 0.009), and SL (p = 0.031) when compared with full-back squat. There was no significant difference for rating of perceived exertion between partial and full back squat exercise at 10RM (8 ± 1 and 9 ± 1, respectively). In conclusion, the range of motion in the back squat alters muscle activation of the prime mover (GM) and stabilizers (SL and BF) when performed with the load equated on a relative basis. Thus, the partial back squat maximizes the level of muscle activation of the GM and associated stabilizer muscles.
[Mh] Termos MeSH primário: Músculo Esquelético/fisiologia
Treinamento de Resistência/métodos
[Mh] Termos MeSH secundário: Adulto
Dorso/fisiologia
Eletromiografia
Exercício/fisiologia
Músculos Isquiotibiais/fisiologia
Seres Humanos
Masculino
Músculo Quadríceps/fisiologia
Amplitude de Movimento Articular/fisiologia
Coxa da Perna/fisiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171101
[Lr] Data última revisão:
171101
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170525
[St] Status:MEDLINE
[do] DOI:10.1519/JSC.0000000000001713


  7 / 4009 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28538320
[Au] Autor:Charlton JM; Hammond CA; Cochrane CK; Hatfield GL; Hunt MA
[Ad] Endereço:Motion Analysis and Biofeedback Laboratory, Department of Physical Therapy, University of British Columbia, Vancouver, British Columbia, Canada.
[Ti] Título:The Effects of a Heel Wedge on Hip, Pelvis and Trunk Biomechanics During Squatting in Resistance Trained Individuals.
[So] Source:J Strength Cond Res;31(6):1678-1687, 2017 06.
[Is] ISSN:1533-4287
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Barbell back squats are a popular exercise for developing lower extremity strength and power. However, this exercise has potential injury risks, particularly to the lumbar spine, pelvis, and hip joint. Previous literature suggests heel wedges as a means of favorably adjusting trunk and pelvis kinematics with the intention of reducing such injury risks. Yet no direct biomechanical research exists to support these recommendations. Therefore, the purpose of this study was to examine the effects of heel wedges compared with barefoot on minimally loaded barbell back squats. Fourteen trained male participants performed a barbell back squat in bare feet or with their feet raised bilaterally with a 2.5-cm wooden block while 3-dimensional kinematics, kinetics, and electromyograms were collected. The heel wedge condition elicited significantly less forward trunk flexion angles at peak knee flexion, and peak external hip joint moments (p ≤ 0.05) compared with barefoot conditions. However, no significant differences were observed between conditions for trunk and pelvis angle differences at peak knee flexion (p > 0.05). Lastly, no peak or root mean square differences in muscle activity were elicited between conditions (p > 0.05). Our results lend support for the suggestions provided in literature aimed at using heel wedges as a means of reducing excessive forward trunk flexion. However, the maintenance of a neutral spine, another important safety factor, is not affected by the use of heel wedges. Therefore, heel wedges may be a viable modification for reduction of excessive forward trunk flexion but not for reduction in relative trunk-pelvis flexion during barbell back squats.
[Mh] Termos MeSH primário: Calcanhar/fisiologia
Pelve/fisiologia
Treinamento de Resistência/métodos
Tronco/fisiologia
[Mh] Termos MeSH secundário: Adulto
Dorso/fisiologia
Fenômenos Biomecânicos

Articulação do Quadril/fisiologia
Seres Humanos
Extremidade Inferior/fisiologia
Vértebras Lombares
Masculino
Postura/fisiologia
Amplitude de Movimento Articular/fisiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171101
[Lr] Data última revisão:
171101
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170525
[St] Status:MEDLINE
[do] DOI:10.1519/JSC.0000000000001655


  8 / 4009 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28499583
[Au] Autor:Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
[Ad] Endereço:Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: alessandro.gronchi@istitutotumori.mi.it.
[Ti] Título:Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
[So] Source:Lancet Oncol;18(6):812-822, 2017 Jun.
[Is] ISSN:1474-5488
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Previous trials from our group suggested an overall survival benefit with five cycles of adjuvant full-dose epirubicin plus ifosfamide in localised high-risk soft-tissue sarcoma of the extremities or trunk wall, and no difference in overall survival benefit between three cycles versus five cycles of the same neoadjuvant regimen. We aimed to show the superiority of the neoadjuvant administration of histotype-tailored regimen to standard chemotherapy. METHODS: For this international, open-label, randomised, controlled, phase 3, multicentre trial, patients were enrolled from 32 hospitals in Italy, Spain, France, and Poland. Eligible patients were aged 18 years or older with localised, high-risk (high malignancy grade, 5 cm or longer in diameter, and deeply located according to the investing fascia), soft-tissue sarcoma of the extremities or trunk wall and belonging to one of five histological subtypes: high-grade myxoid liposarcoma, leiomyosarcoma, synovial sarcoma, malignant peripheral nerve sheath tumour, and undifferentiated pleomorphic sarcoma. Patients were randomly assigned (1:1) to receive three cycles of full-dose standard chemotherapy (epirubicin 60 mg/m per day [short infusion, days 1 and 2] plus ifosfamide 3 g/m per day [days 1, 2, and 3], repeated every 21 days) or histotype-tailored chemotherapy: for high-grade myxoid liposarcoma, trabectedin 1·3 mg/m via 24-h continuous infusion, repeated every 21 days; for leiomyosarcoma, gemcitabine 1800 mg/m on day 1 intravenously over 180 min plus dacarbazine 500 mg/m on day 1 intravenously over 20 min, repeated every 14 days; for synovial sarcoma, high-dose ifosfamide 14 g/m , given over 14 days via an external infusion pump, every 28 days; for malignant peripheral nerve sheath tumour, intravenous etoposide 150 mg/m per day (days 1, 2, and 3) plus intravenous ifosfamide 3 g/m per day (days 1, 2, and 3), repeated every 21 days; and for undifferentiated pleomorphic sarcoma, gemcitabine 900 mg/m on days 1 and 8 intravenously over 90 min plus docetaxel 75 mg/m on day 8 intravenously over 1 h, repeated every 21 days. Randomisation was stratified by administration of preoperative radiotherapy and by country of enrolment. Computer-generated random lists were prepared by use of permuted balanced blocks of size 4 and 6 in random sequence. An internet-based randomisation system ensured concealment of the treatment assignment until the patient had been registered into the system. No masking of treatment assignments was done. The primary endpoint was disease-free survival. The primary and safety analyses were planned in the intention-to-treat population. We did yearly futility analyses on an intention-to-treat basis. The study was registered with ClinicalTrials.gov, number NCT01710176, and with the European Union Drug Regulating Authorities Clinical Trials, number EUDRACT 2010-023484-17, and is closed to patient entry. FINDINGS: Between May 19, 2011, and May 13, 2016, 287 patients were randomly assigned to a group (145 to standard chemotherapy and 142 to histotype-tailored chemotherapy), all of whom, except one patient assigned to standard chemotherapy, were included in the efficacy analysis (97 [34%] with undifferentiated pleomorphic sarcoma; 64 [22%] with high-grade myxoid liposarcoma; 70 [24%] with synovial sarcoma; 27 [9%] with malignant peripheral nerve sheath tumour; and 28 [10%] with leiomyosarcoma). At the third futility analysis, with a median follow-up of 12·3 months (IQR 2·75-28·20), the projected disease-free survival at 46 months was 62% (95% CI 48-77) in the standard chemotherapy group and 38% (22-55) in the histotype-tailored chemotherapy group (stratified log-rank p=0·004; hazard ratio 2·00, 95% CI 1·22-3·26; p=0·006). The most common grade 3 or higher adverse events in the standard chemotherapy group (n=125) were neutropenia (107 [86%]), anaemia (24 [19%]), and thrombocytopenia (21 [17%]); the most common grade 3 or higher adverse event in the histotype-tailored chemotherapy group (n=114) was neutropenia (30 [26%]). No treatment-related deaths were reported in both groups. In agreement with the Independent Data Monitoring Committee, the study was closed to patient entry after the third futility analysis. INTERPRETATION: In a population of patients with high-risk soft-tissue sarcoma, we did not show any benefit of a neoadjuvant histotype-tailored chemotherapy regimen over the standard chemotherapy regimen. The benefit seen with the standard chemotherapy regimen suggests that this benefit might be the added value of neoadjuvant chemotherapy itself in patients with high-risk soft-tissue sarcoma. FUNDING: European Union grant (Eurosarc FP7 278472).
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Neurilemoma/terapia
Sarcoma/patologia
Sarcoma/terapia
Neoplasias de Tecidos Moles/patologia
Neoplasias de Tecidos Moles/terapia
[Mh] Termos MeSH secundário: Parede Abdominal
Adolescente
Adulto
Idoso
Anemia/induzido quimicamente
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Dorso
Quimioterapia Adjuvante/métodos
Criança
Dacarbazina/administração & dosagem
Desoxicitidina/administração & dosagem
Desoxicitidina/análogos & derivados
Dioxóis/administração & dosagem
Intervalo Livre de Doença
Epirubicina/administração & dosagem
Etoposídeo/administração & dosagem
Extremidades
Seres Humanos
Ifosfamida/administração & dosagem
Leiomiossarcoma/terapia
Lipossarcoma Mixoide/terapia
Meia-Idade
Terapia Neoadjuvante/métodos
Neutropenia/induzido quimicamente
Fatores de Risco
Sarcoma Sinovial/terapia
Taxoides/administração & dosagem
Tetra-Hidroisoquinolinas/administração & dosagem
Parede Torácica
Trombocitopenia/induzido quimicamente
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; COMPARATIVE STUDY; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Dioxoles); 0 (Taxoids); 0 (Tetrahydroisoquinolines); 0W860991D6 (Deoxycytidine); 15H5577CQD (docetaxel); 3Z8479ZZ5X (Epirubicin); 6PLQ3CP4P3 (Etoposide); 7GR28W0FJI (Dacarbazine); B76N6SBZ8R (gemcitabine); ID0YZQ2TCP (trabectedin); UM20QQM95Y (Ifosfamide)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170824
[Lr] Data última revisão:
170824
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170514
[St] Status:MEDLINE


  9 / 4009 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28333612
[Au] Autor:Lake J
[Ad] Endereço:Psychiatrist at the Watsonville Medical Clinic in CA. jameslakemd@gmail.com.
[Ti] Título:Practicing Healing-Cleaning the Back of an Elderly Tibetan Woman.
[So] Source:Perm J;21, 2017.
[Is] ISSN:1552-5775
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Terapia por Acupuntura
Atitude do Pessoal de Saúde
Espiritualidade
[Mh] Termos MeSH secundário: Idoso
Dorso
Feminino
Seres Humanos
Tibet
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170913
[Lr] Data última revisão:
170913
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170324
[St] Status:MEDLINE
[do] DOI:10.7812/TPP/16-059


  10 / 4009 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:28329521
[Au] Autor:Winsett F; Dietert J; Tschen J; Swaby M; Bangert CA
[Ad] Endereço:University of Texas, Houston, School of Medicine, Houston, Texas. frank.t.winsett@uth.tmc.edu.
[Ti] Título:A rare case of cutaneous acanthamoebiasis in a renal transplant patient.
[So] Source:Dermatol Online J;23(3), 2017 Mar 15.
[Is] ISSN:1087-2108
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A 35-year-old woman receiving immunosuppressionfor renal transplantation presented with a onemonthhistory of tender skin nodules on herbilateral upper extremities. A skin biopsy revealedgranulomatous inflammation in the deep dermisand the subcutaneous fat with foci of necrosis.Within the foci of necrosis were large histiocytoidstructures with prominent nuclei. Periodic acid-Schiffstain revealed a round organism with a thick capsule,consistent with amoebal trophozoites. Testing withthe Center for Disease Control revealed the organismto be Acanthamoeba. Despite antimicrobial therapy,the patient continued to develop subcutaneousnodules that extended to the lower extremities andtrunk and ultimately extended to the bone, causingacanthamoebal osteomyelitis. Throughout thehospital course, the patient remained neurologicallyintact without evidence of central nervousinvolvement. A diagnosis of isolated disseminatedcutaneous acanthamoebiasis secondary to iatrogenicimmunosuppression was made. Historically, mostcases of granulomatous amoebic encephalitisand cutaneous acanthamoebiasis have occurredin patients with HIV/AIDS. However, with the useof newer and more effective immunosuppressiveregimens, both are occurring more frequently inthe setting of iatrogenic immunosuppression. Therare and isolated cutaneous nature of this patient'spresentation makes this case unique.
[Mh] Termos MeSH primário: Acanthamoeba
Amebíase/diagnóstico
Rejeição de Enxerto/prevenção & controle
Imunossupressores/efeitos adversos
Transplante de Rim
Dermatopatias Parasitárias/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Amebíase/etiologia
Amebíase/patologia
Braço
Dorso
Feminino
Seres Humanos
Dermatopatias Parasitárias/etiologia
Dermatopatias Parasitárias/patologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Immunosuppressive Agents)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171017
[Lr] Data última revisão:
171017
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170323
[St] Status:MEDLINE



página 1 de 401 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde